David N. Shine is chair of the New York Mergers and Acquisitions practice at Paul Hastings. His practice focuses on public and private company mergers and acquisitions, private equity investments, and joint venture transactions. He has substantial experience in the healthcare, aerospace and defense, energy, telecom, and financial services industries. Representative clients have included Merck & Co., Inc., Medco Health Solutions, Inc., Northrop Grumman Corporation, GE Capital, and Vodafone Group plc.
Mr. Shine’s practice has included representations in high profile transactions such as Merck’s US$41 billion acquisition of Schering-Plough, its US$14.2 billion sale of its consumer care business (which included the Claritin, Coppertone and Dr. Scholls brands) and Northrop Grumman’s hostile acquisition of Newport News Shipbuilding, Inc. He has also represented prominent privately held companies in sale transactions including Tishman Construction, Dean & DeLuca, and Scaled Composites (the builder of Virgin Galactic’s “Spaceship One” space tourism vehicle).